On May 14, 2020 Genmab A/S (Nasdaq: GMAB) reported that eight industry sponsored abstracts regarding Genmab and partner programs were accepted for presentation at the 25th European Hematology Association (EHA) (Free EHA Whitepaper) EHA (Free EHA Whitepaper)25 Virtual Congress 2020, taking place virtually on June 11-14, 2020 (Press release, Genmab, MAY 14, 2020, View Source [SID1234557998]). A list of accepted Industry-sponsored abstracts featured at the congress includes two abstracts on epcoritamab (DuoBody-CD3xCD20), one on HexaBody-CD38, one on DuoHexaBody-CD37 and four daratumumab abstracts. The abstracts have been published on the EHA (Free EHA Whitepaper) website and may be accessed via www.ehaweb.org. All e-Poster presentations will be made available on the on-demand Virtual Congress platform Friday, June 12 at 08:30 CEST.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased to see that once again a broad spectrum of data from Genmab’s innovative clinical and pre-clinical proprietary pipeline has been accepted for presentation at the prestigious EHA (Free EHA Whitepaper) Congress," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Industry-Sponsored Abstracts are as follows:
Epcoritamab (DuoBody-CD3xCD20):
Subcutaneous epcoritamab (DuoBody-CD3×CD20) induces complete response in heavily pre-treated patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma: Phase 1/2 dose escalation
Evaluation of pharmacodynamic biomarkers of epcoritamab (GEN3013; CD3CD20): Results from a Phase 1/2 dose-escalation study in relapsed/refractory B-cell Non-Hodgkin Lymphoma
HexaBody-CD38:
Superior anti-tumor activity of HexaBody-CD38 in preclinical models of Multiple Myeloma, B Cell Lymphoma and AML
DuoHexaBody-CD37:
DuoHexaBody-CD37 shows potent anti-tumor activity in pre-clinical B-cell lymphoma models in vitro and in vivo
Daratumumab (Submitted by Janssen Biotech, Inc.):
Phase 3 Study of Daratumumab/Bortezomib/Dexamethasone Versus Bortezomib/Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma: MMY3009 (LEPUS)
Corticosteriod Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-label, Multicenter, Phase 1b PAVO Study
Impact of Depth of Response and Minimal Residual Disease on Health-Related Quality of Life of Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma
Daratumumab + Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma: Baseline slimCRAB-based Subgroup Analysis of CASSIOPEIA